Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Overview

This study will investigate the efficacy of treatment with octroetide in patients with primary inoperable thymoma to reduce tumor size.

Full Title of Study: “Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2010

Interventions

  • Drug: Octreotide

Arms, Groups and Cohorts

  • Experimental: Sandostatin

Clinical Trial Outcome Measures

Primary Measures

  • Shrinkage of tumor size and diameter of 3 respectively 6 months
    • Time Frame: 6 months

Secondary Measures

  • Resection status after 3 respectively 6 months
    • Time Frame: 3 – 6 months

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female patients aged >18 years 2. Inoperability of thymic tumor. Inoperability is defined as at least adherence of the tumor to the neighbour organs, suspicious to infiltrate neighbour organs so that R0 resection cannot be expected. 3. Positive result in SMS-szintigraphy, 4. Thymomas of all WHO based histological subtypes (Rosai, 1999; Travis 2004) at Masaoka stage III based on histological examination of core biopsies or resection specimens. 5. Patients with and without thymoma associated paraneoplastic syndrome 6. Demonstrated tolerance to a test dose of s.c. octreotide injection at Visit 1. Exclusion Criteria:

1. Performance status 0,1, or 2 (ECOG) 2. Symptomatic cholelithiasis, 3. Pretreatment with octreotide (longn acting release) within the 3 months 4. Patient has received any other investigational agents within 28 days of first day of study drug dosing 5. Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed 6. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study) Other protocol-defined inclusion/exclusion criteria apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmeceuticals

Citations Reporting on Results

Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Strobel P, May C, Kleylein-Sohn J, Baierlein C, Bogdahn U, Marx A, Schalke B. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS One. 2016 Dec 16;11(12):e0168215. doi: 10.1371/journal.pone.0168215. eCollection 2016.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.